OLANZAPINE TEVA ® 7.5 MG

Country: Iżrael

Lingwa: Ingliż

Sors: Ministry of Health

Ingredjent attiv:

OLANZAPINE 7.5 MG

Disponibbli minn:

SALOMON,LEVIN & ELSTEIN LTD

Kodiċi ATC:

N05AH03

Għamla farmaċewtika:

FILM COATED TABLETS

Rotta amministrattiva:

PER OS

Manifatturat minn:

TEVA OPERATIONS POLAND SP.ZO.O

Grupp terapewtiku:

OLANZAPINE

Indikazzjonijiet terapewtiċi:

Acute and maintenance treatment of schizophrenia. Olanzapine Teva® is indicated for the management of the manifestations of psychotic disorders. Olanzapine Teva® is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.Prevention of recurrence in Bipolar Disorder: In patients whose manic episode has responded to olanzapine treatment Olanzapine Teva® is indicated for the prevention of recurrence in patients with Bipolar Disorder. Combination therapy in Bipolar I Disorder. The combination of Olanzapine Teva® with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.

Data ta 'l-awtorizzazzjoni:

2011-04-01